API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. F /
  3. 0PT.F

Prothena Corporation plc (0PT F) stock market data APIs

€16 -0.3(-1.8%) as of November 8, 2024
Price chart is built with Anychart

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc Financial Data Overview

16.3
16
-
16.3
16
14.1-37
882 M
53 780 K
217 M
0.158
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '0PT',
Type: 'Common Stock',
Name: 'Prothena Corporation plc',
Exchange: 'F',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: 'IE00B91XRN20',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Prothena Corporation plc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 217 M
  • EBITDA -90 407 000
  • Earnings Per Share -0.87
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Prothena Corporation plc Earnings via APIs

  • Latest Release 2024-11-04
  • EPS/Forecast NaN

Get Prothena Corporation plc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Prothena Corporation plc latest news via APIs

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

Biogen BIIB and partner Eisai recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delayed the decision on their Alzheimer’s dise...

Prothena Appoints David Ford to Newly Created Chief People Officer Position

David Ford, Chief People Officer, Prothena (Photo: Business Wire) DUBLIN, March 04, 2024--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a r...
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com